TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $65
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $65.
TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $50 to $65.